Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy - 12/01/23
, Javed Butler, MD MPH b, c, Stefano Del Prato, MD d, Justin A. Ezekowitz, MB BCh e, Nasrien E. Ibrahim, MD f, Carolyn S.P. Lam, MBBS PhD g, Gregory D. Lewis, MD h, Thomas H. Marwick, MBBS PhD MPH i, Julio Rosenstock, MD j, W.H. Wilson Tang, MD k, Faiez Zannad, MD PhD l, Francesca Lawson, MD m, Riccardo Perfetti, MD PhD m, Alessia Urbinati, MD mRésumé |
Background |
Diabetic cardiomyopathy (DbCM) is a specific form of heart muscle disease that may result in substantial morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Hyperactivation of the polyol pathway is one of the primary mechanisms in the pathogenesis of diabetic complications, including development of DbCM. There is an unmet need for therapies targeting the underlying metabolic abnormalities that drive this form of Stage B heart failure (HF).
Methods |
Aldose reductase (AR) catalyzes the first and rate-limiting step in the polyol pathway, and AR inhibition has been shown to reduce diabetic complications, including DbCM in animal models and in patients with DbCM. Previous AR inhibitors (ARIs) were limited by poor specificity resulting in unacceptable tolerability and safety profile. AT-001 is a novel investigational highly specific ARI with higher binding affinity and greater selectivity than previously studied ARIs. ARISE-HF (NCT04083339) is an ongoing Phase 3 randomized, placebo-controlled, double blind, global clinical study to investigate the efficacy of AT-001 (1000 mg twice daily [BID] and 1500 mg BID) in 675 T2DM patients with DbCM at high risk of progression to overt HF. ARISE-HF assesses the ability of AT-001 to improve or prevent decline in exercise capacity as measured by functional capacity (changes in peak oxygen uptake [peak VO2]) over 15 (and possibly 27) months of treatment. Additional endpoints include percentage of patients progressing to overt HF, health status metrics, echocardiographic measurements, and changes in cardiacbiomarkers.
Results |
The ARISE-HF Trial is fully enrolled.
Conclusions |
This report describes the rationale and study design of ARISE-HF.
Le texte complet de cet article est disponible en PDF.Plan
Vol 256
P. 25-36 - février 2023 Retour au numéro
Article précédent
- Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) – Diabetes: rationale and design
- Adam J. Nelson, Neha J. Pagidipati, Michelle D. Kelsey, Maddalena Ardissino, Vanita R. Aroda, Matthew A. Cavender, Renato D. Lopes, Hussein R. Al-Khalidi, Rogelio Braceras, Tanya Gaynor, Lisa A. Kaltenbach, Julienne K. Kirk, Ildiko Lingvay, Melissa L. Magwire, Emily C. O'Brien, Jonathan Pak, Rodica Pop-Busui, Caroline R. Richardson, Monica Levya, Cagri Senyucel, Laura Webb, Darren K. McGuire, Jennifer B. Green, Christopher B. Granger
- Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease–2
- Upendra Kaul, Priyadarshini Arambam, Santosh Kumar Sinha, Rajpal Abhaichand, Ashok Kumar Parida, Darshan Banker, Rohit Mody, Aziz Khan, Rajesh Sharma, Nagaraja Moorthy, Sharad Chandra, Sarat Chandra Koduganti, Rajeev Garg, Polavarapu Raghava Sarma, Deepesh Kumar Agrawal, K M K Reddy, Sripal Bangalore
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?